The Food and Drug Administration has provided guidance to Provectus Pharmaceuticals as the drug maker prepares to apply with the agency for approval to start a late-stage clinical trial of a drug for skin cancer, Provectus said Wednesday.
Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.
Laurry Hinds has been named regional director at BioPlus Specialty Pharmacy, responsible for business development in western North Carolina, the company announced.
Bristol-Myers Squibb has officially launched its tender offer for Inhibitex, the drug maker said Friday.
Drug maker Octapharma USA has appointed David Holliday as VP commercial development, the company said.
Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.
Generic drug maker Hospira has enrolled the first patient in a late-stage clinical trial of a biosimilar drug for treating kidney disease.
Diplomat Specialty Pharmacy has received limited distribution rights for a neovascular age-related macular degeneration treatment.
Endo Pharmaceuticals announced a short-term supply constraint of analgesic products, including Opana ER, due to the temporary shutdown of a manufacturing facility operated by Novartis Consumer Health.
Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.